IMA:NASDAQ, ImageneBio Inc.

Why IMA stock rose on November 17

ImageneBio Inc. rose 21.9% on Tuesday, November 17, 2026, on 90,400 shares, 5.8 times its average daily volume. No headline about IMA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

IMA stock overview

ImageneBio Inc. (IMA:NASDAQ) closed at $3.92 on November 20, 2026, unchanged on the day. The stock trades 48.4% below its 52-week high of $7.60 and 30.7% above its 52-week low of $3.00. Over the past year, it lost 43.3%. ImageneBio Inc. is part of the Health Care sector.

Key figures

Price
$3.92
Day change
0.00%
Volume
44,335
Average volume
15,479
Market cap
48M+
52-week range
$3.00 – $7.60
50-day average
$4.29
200-day average
$5.41

Price action over the past year

In 252 trading sessions since November 20, 2025, IMA closed higher on 104 days (41%). Its best day was April 13, 2026 (+23.42%) and its worst was May 8, 2026 (-10.49%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

IMA news

About ImageneBio Inc.

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

Similar stocks

Find more stocks like IMA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.